Zhiyuan Zheng1,2, Xuesong Han1, Gery P Guy3, Amy J Davidoff4, Chunyu Li3, Matthew P Banegas5, Donatus U Ekwueme3, K Robin Yabroff6, Ahmedin Jemal1. 1. Surveillance and Health Services Research Program, American Cancer Society, Atlanta, Georgia. 2. University of Maryland School of Pharmacy, Baltimore, Maryland. 3. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. 4. Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut. 5. The Center for Health Research, Kaiser Permanente, Portland, Oregon. 6. Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland.
Abstract
BACKGROUND: There is limited evidence from nationally representative samples about changes in prescription drug use for financial reasons among cancer survivors in the United States. METHODS: The 2011 to 2014 National Health Interview Survey was used to identify adults who reported ever having been told they had cancer (cancer survivors; n = 8931) and individuals without a cancer history (n = 126,287). Measures of changes in prescription drug use for financial reasons included: 1) skipping medication doses, 2) taking less medicine, 3) delaying filling a prescription, 4) asking a doctor for lower cost medication, 5) buying prescription drugs from another country, and 6) using alternative therapies. Multivariable logistic regression analyses were controlled for demographic characteristics, number of comorbid conditions, interactions between cancer history and number of comorbid conditions, and health insurance coverage. Main analyses were stratified by age (nonelderly, ages 18-64 years; elderly, ages ≥65 years) and time since diagnosis (recently diagnosed, <2 years; previously diagnosed, ≥2 years). RESULTS: Among nonelderly individuals, both recently diagnosed (31.6%) and previously diagnosed (27.9%) cancer survivors were more likely to report any change in prescription drug use for financial reasons than those without a cancer history (21.4%), with the excess percentage changes for individual measures ranging from 3.5% to 9.9% among previously diagnosed survivors and from 2.6% to 2.7% among recently diagnosed survivors (P < .01). Elderly cancer survivors and those without a cancer history had comparable rates of changes in prescription drug use for financial reasons. CONCLUSIONS: Nonelderly cancer survivors are particularly vulnerable to changes in prescription drug use for financial reasons, suggesting that targeted efforts are needed. Cancer 2017;123:1453-1463.
BACKGROUND: There is limited evidence from nationally representative samples about changes in prescription drug use for financial reasons among cancer survivors in the United States. METHODS: The 2011 to 2014 National Health Interview Survey was used to identify adults who reported ever having been told they had cancer (cancer survivors; n = 8931) and individuals without a cancer history (n = 126,287). Measures of changes in prescription drug use for financial reasons included: 1) skipping medication doses, 2) taking less medicine, 3) delaying filling a prescription, 4) asking a doctor for lower cost medication, 5) buying prescription drugs from another country, and 6) using alternative therapies. Multivariable logistic regression analyses were controlled for demographic characteristics, number of comorbid conditions, interactions between cancer history and number of comorbid conditions, and health insurance coverage. Main analyses were stratified by age (nonelderly, ages 18-64 years; elderly, ages ≥65 years) and time since diagnosis (recently diagnosed, <2 years; previously diagnosed, ≥2 years). RESULTS: Among nonelderly individuals, both recently diagnosed (31.6%) and previously diagnosed (27.9%) cancer survivors were more likely to report any change in prescription drug use for financial reasons than those without a cancer history (21.4%), with the excess percentage changes for individual measures ranging from 3.5% to 9.9% among previously diagnosed survivors and from 2.6% to 2.7% among recently diagnosed survivors (P < .01). Elderly cancer survivors and those without a cancer history had comparable rates of changes in prescription drug use for financial reasons. CONCLUSIONS: Nonelderly cancer survivors are particularly vulnerable to changes in prescription drug use for financial reasons, suggesting that targeted efforts are needed. Cancer 2017;123:1453-1463.
Authors: Dana P Goldman; Geoffrey F Joyce; Grant Lawless; William H Crown; Vincent Willey Journal: Health Aff (Millwood) Date: 2006 Sep-Oct Impact factor: 6.301
Authors: Gabriel A Brooks; Ling Li; Dhruv B Sharma; Jane C Weeks; Michael J Hassett; K Robin Yabroff; Deborah Schrag Journal: J Natl Cancer Inst Date: 2013-03-12 Impact factor: 13.506
Authors: S Yousuf Zafar; Rebecca B McNeil; Catherine M Thomas; Christopher S Lathan; John Z Ayanian; Dawn Provenzale Journal: J Oncol Pract Date: 2014-12-16 Impact factor: 3.840
Authors: S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy Journal: Oncologist Date: 2013-02-26
Authors: Matthew P Banegas; John F Dickerson; Nicole L Friedman; David Mosen; Althea X Ender; T Ruth Chang; Tracy A Runge; Mark C Hornbrook Journal: Perm J Date: 2019
Authors: Christine Leopold; Anita K Wagner; Fang Zhang; Christine Y Lu; Craig C Earle; Larissa Nekhlyudov; Dennis Ross-Degnan; J Frank Wharam Journal: Breast Cancer Res Treat Date: 2018-06-01 Impact factor: 4.872
Authors: Matthew P Banegas; Jennifer L Schneider; Alison J Firemark; John F Dickerson; Erin E Kent; Janet S de Moor; Katherine S Virgo; Gery P Guy; Donatus U Ekwueme; Zhiyuan Zheng; Alexandra M Varga; Lisa A Waiwaiole; Stephanie M Nutt; Aditi Narayan; K Robin Yabroff Journal: J Cancer Surviv Date: 2019-05-23 Impact factor: 4.442
Authors: Ryan D Nipp; Amy M Shui; Giselle K Perez; Anne C Kirchhoff; Jeffrey M Peppercorn; Beverly Moy; Karen Kuhlthau; Elyse R Park Journal: JAMA Oncol Date: 2018-06-01 Impact factor: 31.777
Authors: Theresa A Hastert; Matthew P Banegas; Lauren M Hamel; Amanda R Reed; Tara Baird; Jennifer L Beebe-Dimmer; Ann G Schwartz Journal: J Cancer Surviv Date: 2019-05-29 Impact factor: 4.442
Authors: Brandon A Sherrod; Nicholas T Gamboa; Christopher Wilkerson; Herschel Wilde; Mohammed A Azab; Michael Karsy; Randy L Jensen; Sarah T Menacho Journal: J Neurooncol Date: 2019-05-04 Impact factor: 4.130
Authors: Matthew P Banegas; John F Dickerson; Erin E Kent; Janet S de Moor; Katherine S Virgo; Gery P Guy; Donatus U Ekwueme; Zhiyuan Zheng; Stephanie Nutt; Loyce Pace; Alexandra Varga; Lisa Waiwaiole; Jennifer Schneider; K Robin Yabroff Journal: J Cancer Surviv Date: 2017-08-29 Impact factor: 4.442
Authors: Alexandra M Psihogios; Lisa A Schwartz; Kylie B Ewing; Bryn Czerniecki; Leslie S Kersun; Ahna L H Pai; Janet A Deatrick; Lamia P Barakat Journal: J Adolesc Young Adult Oncol Date: 2020-05-11 Impact factor: 2.223